A. Beckers

发表

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies

F. Westermann, F. Speleman, L. Klein-Hitpass, 2014, Oncogene.

The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease

Sangkyun Lee, F. Speleman, B. Menten, 2017, Oncotarget.

RNA expression signatures and posttranscriptional regulation in diabetic nephropathy.

M. Rudnicki, J. Vandesompele, H. Neuwirt, 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time

J. Vandesompele, N. Lumen, V. Fonteyne, 2018, World Journal of Urology.

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

F. Westermann, S. Agarwal, F. Speleman, 2015, Cancer letters.

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation

F. Speleman, J. Vandesompele, K. De Preter, 2014, Oncotarget.

MiR‐137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A

R. Stallings, F. Speleman, J. Vandesompele, 2013, International journal of cancer.

Targeting tachykinin receptors in neuroblastoma

F. Speleman, J. Struck, A. Bergmann, 2016, Oncotarget.

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

F. Westermann, F. Speleman, R. Koche, 2015, Clinical Cancer Research.

MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation

F. Speleman, K. De Preter, B. Abraham, 2021, Cancers.

Unraveling the MYCN-driven transcriptional landscape of neuroblastoma : a cross-species integrated transcriptome approach

A. Beckers, 2015 .

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

David Camacho Trujillo, F. Speleman, O. Delattre, 2015, Clinical Cancer Research.

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma

H. Allgayer, M. Schwab, F. Speleman, 2016, Oncotarget.

Glutathione biosynthesis is upregulated at the initiation of MYCN‐driven neuroblastoma tumorigenesis

F. Speleman, M. Pajic, J. Fletcher, 2016, Molecular oncology.

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma

F. Speleman, M. Fischer, A. Oberthuer, 2015, Science Translational Medicine.

Differential module analysis in neuroblastoma regulatory networks

Y. Saeys, Robrecht Cannoodt, K. D. Preter, 2014 .

miR‐542‐3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin

F. Speleman, J. Vandesompele, P. Mestdagh, 2015, International journal of cancer.

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma

F. Speleman, J. Schulte, A. Eggert, 2013, Oncotarget.

Plasma miRNAs as biomarkers for endometriosis

A. Fassbender, C. Meuleman, T. D’Hooghe, 2019, Human reproduction.

Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.

F. Speleman, Z. Nagy, Bing Liu, 2018, Cancer research.

The need for transparency and good practices in the qPCR literature

Erik Willems, Jo Vandesompele, Jim Huggett, 2013, Nature Methods.

miRBase Tracker: keeping track of microRNA annotation changes

Jo Vandesompele, Pieter Mestdagh, Pieter-Jan Volders, 2014, Database J. Biol. Databases Curation.

Effective Alu Repeat Based RT-Qpcr Normalization in Cancer Cell Perturbation Experiments

F. Speleman, J. Vandesompele, F. Pattyn, 2013, PloS one.

Model-Based Classification for Digital PCR: Your Umbrella for Rain.

Els Goetghebeur, Lieven Clement, Nina Papazova, 2017, Analytical chemistry.

The MYCN/miR-26a-5p/LIN28B regulatory axis controls MYCN-driven LIN28B upregulation in neuroblastoma

F. Speleman, J. Vandesompele, K. D. Preter, 2014 .

Glutathione biosynthesis is upregulated at the initiation of MYCN‐driven neuroblastoma tumorigenesis

F. Speleman, M. Pajic, J. Fletcher, 2016, Molecular Oncology.

Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome

A. Masclee, Z. Helyes, D. Keszthelyi, 2017, Alimentary pharmacology & therapeutics.

Model-Based Classification for Digital PCR: Your Umbrella for Rain.

E. Goetghebeur, J. Vandesompele, L. Clement, 2017, Analytical chemistry.

Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma

K. De Preter, M. Haber, M. Norris, 2023, International journal of molecular sciences.

Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time

J. Vandesompele, N. Lumen, V. Fonteyne, 2018, World Journal of Urology.

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation

F. Speleman, J. Vandesompele, K. De Preter, 2014, Oncotarget.